Healthcare
Mineralys Therapeutics, Inc.(MLYS)
Live Price
Offline$24.63
-1.99% today
1Y Change
+72.96%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.94B
- Revenue Growth
- 0.0%
- EPS Growth
- +37.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mineralys Therapeutics, Inc. (MLYS) is a Healthcare stock with a market cap of $1.94B and listed on NASDAQ. The stock last traded around $24.63 and up 73.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.4%, free cash flow +14.4% with operating margin 0.0% and ROIC -26.4%. Stock Foundry combines MLYS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +37.4%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.6% | -11.2% | -18.7% |
2026 Mar 12, 2026 | +22.5% | -3.0% | -13.7% | -1.4% |
2025 Nov 10, 2025 | +21.2% | +5.9% | -0.5% | -17.5% |
Benchmark Edge
MLYS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MLYS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MLYS Max Drawdown
-52.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MLYS and SPY.
Company Overview
Mineralys Therapeutics, Inc.
NASDAQ Global Select
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Leadership
- Jon Congleton
- IPO Date
- Feb 10, 2023
- Employees
- 51
- Street Address
- 150 N. Radnor Chester Rd.
- Mailing
- Radnor, PA, 19087
- Region
- Radnor, PA, US
- Reporting Currency
- USD
- Investor Line
- 888-378-6240
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.6
Growth
- Revenue
- 0.0%
- EPS
- +37.4%
- Free Cash Flow
- +14.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -32.9%
- ROIC
- -26.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 43.76
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.